Neoadjuvant Therapies Do Not Reduce Epidermal Growth Factor Receptor (EGFR) Expression or EGFR-Targeted Fluorescence in a Murine Model of Soft-Tissue Sarcomas.

Samuel S StreeterXiaochun XuKendra A HebertPaul M WerthP Jack HoopesLesley A JarvisBrian W PogueKeith D PaulsenKimberley S SamkoeEric R Henderson

Published in: Molecular imaging and biology (2023)

Results suggest that ABY-029 as an EGFR-targeted, fluorescent probe is not negatively impacted by neoadjuvant soft-tissue sarcoma therapies, although validation in humans is required.

Keyphrases

epidermal growth factor receptor
fluorescent probe
tyrosine kinase
advanced non small cell lung cancer
rectal cancer
living cells
locally advanced
soft tissue
lymph node
cancer therapy
poor prognosis
single molecule
squamous cell carcinoma